Results 11 to 20 of about 27,271 (263)

Circulating TIGIT±PD1+TPH, TIGIT ± PD1+TFH cells are elevated and their predicting role in systemic lupus erythematosus

Heliyon
It is well established that increased peripheral helper T cells (TPH) and follicular helper T cells (TFH) was found in systemic lupus erythematosus (SLE) patients. However, the expression patterns and immunomodulatory roles of TIGIT and PD1 on TPH/TFH in
Qing Luo, Qiuyun Xiao, Lu Zhang, Biqi Fu, Xue Li, Zikun Huang, Junming Li   +6 more
doaj   +3 more sources

TIGIT blockade improves anti-Mycobacterium tuberculosis immunity.

PLoS Pathogens
Despite the therapeutic benefit of immune checkpoint blockade in cancers, there is no consensus on its effect in infectious diseases. Here we investigated whether blocking the immune checkpoint T cell immunoreceptor with immunoglobulin and immunoreceptor
Jingyu Zhou, Qingluan Yang, Haoxin Xu, Huaxin Chen, Ning Jiang, Qinfang Ou, Mengqing Qian, Xing Lin, Yixuan Yang, Feiran Zhou, Yuzhen Xu, Qianqian Liu, Yuanyuan Liu, Yan Gao, Wenhong Zhang, Lingyun Shao, Qiaoling Ruan   +16 more
doaj   +3 more sources

TIGIT in cancer immunotherapy [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cells’ survival and function.
Joe-Marc Chauvin, Hassane M Zarour
openaire   +3 more sources

The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction

Biochemical and Biophysical Research Communications, 2021
Although the PVR/TIGIT immune checkpoint axis has been suggested as a promising target for cancer immunotherapy and multiple TIGIT-targeting therapies are undergoing clinical trials, the underlying regulatory mechanisms of PVR/TIGIT interaction remain inconclusive.
Yu-Xi Lin, Mien-Chie Hung, Jye-Lin Hsu, Jung-Mao Hsu   +3 more
openaire   +2 more sources

TIGIT blockade repolarizes AML-associated TIGIT⁺ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Background Leukemia-associated macrophages (LAMs) represent an important cell population within the tumor microenvironment, but little is known about the phenotype, function, and plasticity of these cells. The present study provides an extensive characterization of macrophages in patients with acute myeloid leukemia
Franziska Brauneck, Brit Fischer, Marius Witt, Jana Muschhammer, Jennyfer Oelrich, Pedro Henrique da Costa Avelar, Sophia Tsoka, Lars Bullinger, Elisa Seubert, Daniel J Smit, Carsten Bokemeyer, Christin Ackermann, Jasmin Wellbrock, Friedrich Haag, Walter Fiedler   +14 more
openaire   +3 more sources

TIGIT as an emerging immune checkpoint [PDF]

Clinical and Experimental Immunology, 2019
Summary T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to down-regulate T cell and natural killer (NK ...
H Harjunpää, C Guillerey
openaire   +4 more sources

TIGIT-based immunotherapeutics in lung cancer

Immunotherapy Advances, 2023
Summary In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by the advent of PD-1/PD-L1 ...
Akshay J Patel, Gary W Middleton
openaire   +2 more sources

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity [PDF]

Pharmaceuticals, 2021
Tumors escape immune surveillance by inducing various immunosuppressive pathways, including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal antibodies (mAbs) blocking programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) have been approved for ...
Jinah Yeo, Minkyung Ko, Dong-Hee Lee, Yoon Park, Hyung-seung Jin   +4 more
openaire   +3 more sources

TIGIT in Lung Cancer: Potential Theranostic Implications

Life, 2023
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppression of immune responses.
Carlo Pescia, Giuditta Pini, Edoardo Olmeda, Stefano Ferrero, Gianluca Lopez   +4 more
openaire   +3 more sources

Treatment of murine lupus with TIGIT-Ig [PDF]

Clinical Immunology, 2019
AbstractThe TIGIT (T cell immunoreceptor with Ig and ITIM domains) protein is a co-inhibitory receptor that has been reported to suppress autoreactive T and B cells to trigger immunological tolerance. We generated a new recombinant protein by connecting the extracellular domain of murine TIGIT to the Fc region of the rat immunoglobulin IgG2a.
Liu, Shuowu, Sun, Lizhu, Wang, Chuqi, Cui, Yingshu, Ling, Yuee, Li, Tian, Lin, Fangxing, Fu, Wenyan, Ding, Min, Zhang, Shuyi, Lei, Changhai, Hu, Shi   +11 more
openaire   +2 more sources